Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer

11Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Background: The role of second-line therapy in metastatic pancreatic cancer is not clear. In this study, we aimed to explore the second-line efficiency of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer who have received gemcitabine-based first-line therapy. Materials and Methods: We retrospectively evaluated 47 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine-based first-line regimens. Treatment consisted of oxaliplatin 130 mg/m2 and capecitabine 1000 mg/m2 twice daily with a 3 week interval, until unacceptable toxicity or disease progression. Results: Median number of cycles was 4 (range, 2-10). The overall disease control rate was 38.3%. The median overall survival and progression-free survival from the start of second-line therapy were 23 weeks (95%CI: 16.6-29.5 weeks) and 12 weeks (95%CI: 9.8-14.4 weeks), respectively. The most common grade 3-4 toxicities were nausea, vomiting and hematologic side effects. Conclusions: Our result suggests that the combination of capecitabine and oxaliplatin was tolerated with manageable toxicity and showed encouraging activity as second-line treatment of advanced or metastatic pancreatic cancer patients with ECOG performance status 0-2.

Cite

CITATION STYLE

APA

Bayoglu, I. V., Varol, U., Yildiz, I., Muslu, U., Alacacioglu, A., Kucukzeybek, Y., … Tarhan, M. O. (2014). Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. Asian Pacific Journal of Cancer Prevention, 15(17), 7119–7123. https://doi.org/10.7314/APJCP.2014.15.17.7119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free